BRIEF—Leqembi picks up new nod in Israel

Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong.

Leqembi, targeting amyloid-beta plaques, is designed for early-stage Alzheimer's patients, including those with mild cognitive impairment or mild dementia.

The approval is based on results from the Phase III Clarity AD study, where Leqembi met its primary and key secondary endpoints with statistically significant results.

Eisai leads the global development and regulatory submissions of Leqembi, with both companies co-commercializing the drug. Eisai will handle its commercialization in Israel.